Capricor Therapeutics, Inc. (CAPR )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CAPR
- Company Capricor Therapeutics, Inc.
- Price $6.84
- Changes Percentage -14.35
- Change -1.145
- Day Low $6.83
- Day High $7.8
- Year High $40.37
- Year Low $4.3
- Market Cap $333,566,753
- Price Avg 50 EMA (D) $24.99
- Price Avg 200 EMA (D) $23.32
- Exchange NASDAQ
- Volume 6,236,208
- Average Volume 1,813,808
- Open $7.66
- Previous Close $7.98
- EPS -2.32
- PE -2.48
- Earnings Announcement 2026-08-11 20:00:00
- Shares Outstanding $57,911,900
Company brief: CAPRICOR THERAPEUTICS, INC. (CAPR )
- Healthcare
- Biotechnology
- Dr. Linda Marbán Ph.D.
- https://www.capricor.com
- US
- N/A
- 02-13-2007
- US14070B3096
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
CAPR Corporation News
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman
newsfilecorp.com -- San Francisco, California--(Newsfile Corp. - August 19, 2026) - National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Followin...